Education
About Us
Working with TipRanks
Follow Us
Lynx1 Capital Management LP Insider Profile
11 Followers
Lynx1 Capital Management LP, Ten Percent Owner at TScan Therapeutics, holds 8.96M shares in Cullinan Management (Ticker: CGEM), holds 875.33K shares in Neuphoria Therapeutics (Ticker: NEUP), holds 623.70K shares in Passage Bio (Ticker: PASG). Most recently, Lynx1 Capital Management LP Bought ― shares of Cullinan Management on Oct 30, 2025 for an estimated value of $1.39M.
Lynx1 Capital Management LP TScan Therapeutics (TCRX)Ten Percent Owner
TScan Therapeutics (TCRX)
Ten Percent Owner
Ranked #88,773 out of 104,104 Corporate Insiders
Profitable Transactions
5 out of 11 Profitable Transactions
Average Return
-18.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lynx1 Capital Management LP holds in companies
Most Profitable Insider Trade
The most profitable trade made by Lynx1 Capital Management LP
Lynx1 Capital Management LP's Trading History
TScan Therapeutics
May 21, 2025
Ten Percent Owner
Informative Buy
3.11M
$8.66M
Passage Bio
Sep 15, 2025
Ten Percent Owner
Informative Buy
223.60K
$3.92M
Cullinan Management
Oct 30, 2025
Ten Percent Owner
Informative Buy
1.39M
$64.45M
Neuphoria Therapeutics
Oct 23, 2025
Ten Percent Owner
Informative Buy
3.28M
$3.59M
List of latest transactions for each holding click on a transaction to see Lynx1 Capital Management LP's performance on stock
You May Also Like
Lynx1 Capital Management LP insider profile FAQ
What is the percentage of profitable transactions made by Lynx1 Capital Management LP?
The percentage of profitable transactions made by Lynx1 Capital Management LP is 45%.
What is the average return per transaction made by Lynx1 Capital Management LP?
The average return per transaction made by Lynx1 Capital Management LP is -18.40%.
What stocks does Lynx1 Capital Management LP hold?
Lynx1 Capital Management LP holds: TCRX, PASG, CGEM, NEUP stocks.
What was Lynx1 Capital Management LP’s latest transaction?
Lynx1 Capital Management LP latest transaction was an Informative Buy of $1.39M.
What was Lynx1 Capital Management LP's most profitable transaction?
Lynx1 Capital Management LP’s most profitable transaction was an Informative Buy of TCRX stock on May 21, 2025. The return on the trade was 75.00%.
What is Lynx1 Capital Management LP's role in TScan Therapeutics?
Lynx1 Capital Management LP's role in TScan Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.